P-Y McLaughlin

Long-term disease-free survival and health-related quality of life results of HDR brachytherapy as monotherapy pubmed.ncbi.nlm.nih.gov/39547869/ Long term outcomes for prospective trial of HDR monotherapy - very reassuring outcomes, despite most patients not being MR-staged at the time

Calling all Brachytherapists, 15 year results from ascende RT presented by #scotttyldesley showing continued biochemical PFS, no OS benefit but benefit in prostate cancer specific deaths. @AmericanBrachy @ASTRO_org

@stats_feed A variation/rip-off of @JoeListComedy ‘s bit?

Pablo Picasso was alive when Snoop Dogg was born.

Excited to share our latest work in Advances in Radiation Oncology! 🚀 We compared outcomes of 5-fraction adaptive MRI-guided RT for newly diagnosed glioblastoma vs. 15- & 30-fraction regimens using propensity score matching. 📄doi.org/10.1016/j.adro…

What if this was a drug ?🙂 🆕 NEJM | June 2025 🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon cancer 📦 RCT | n=889 | Median FU: 7.9 yrs 🟠 3-yr structured aerobic program vs health ed alone 📈 Primary Endpoint: Disease-Free Survival (DFS) 🔹 HR 0.72 (95% CI: 0.55–0.94), p=0.02 🔹 5-yr DFS: 80.3% vs 73.9% (+6.4%) 🟨 Overall Survival (OS) 🔸 HR 0.63 (95% CI: 0.43–0.94) 🔸 8-yr OS: 90.3% vs 83.2% (+7.1%) 🧠 Other highlights: 🔻 ↓ Liver recurrence: 3.6% vs 6.5% 🔻 ↓ New primary cancers: 5.2% vs 9.7% 🔻 Improved cardiorespiratory fitness, QoL, 6-min walk ⚠️ AEs: ↑ MSK issues (18.5% vs 11.5%), mostly mild No major safety concerns 🤔 What if this was a drug? 📢 “Breakthrough” 💰 $120K/year 📄 Fast-track approval Instead, it’s just structured EXERCISE. 💡 Prescribe it like we would any other adjuvant therapy. Congratulations to Authors and Dr Chris Booth 👏 #CHALLENGEtrial #ASCO25 @csoncol @oncology_bg @ASCO #ASCO25 @OncoAlert

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: nej.md/4mh5RPL @ASCO

@drdrew Gleason 9 prostate cancer is by definition rapidly progressive. It can missed on screening (often normal or only slightly elevated PSA; nodule/symptoms appearing in months). I see this in practice 1-2x/month as a radiation oncologist. Way to fall into the political spin.

I have prostate cancer. I had a prostatectomy 12 years ago. I've helped patients with prostate cancer for 40 years. If caught early, it is very treatable. So this story about doctors finding a nodule & suddenly Pres. Biden has metastatic disease? It doesn't pass the sniff test.

@iamcoriarnold If only we this was combined with meaningful US deficit and debt reduction, but this won’t happen . A few trillion will be added to the debt by this administration if plan goes through with tax cuts, etc. Also, 2026 elections will go badly for the Rs and tariffs will be reversed

Too many people focus on the negatives when it comes to tariffs - People are living in fear - The stock market is falling But, what if these are a good thing in the long term? Below are 5 good things that come from tariffs:

Our article on long-term outcomes of the 44/20 and 20/0 randomized trials involving prostate brachytherapy has been published in Practical Radiation Oncology! authors.elsevier.com/a/1k5Jd6hRQmwM… @AmericanBrachy

@NiuSanford The inpatient RO ward is a dwindling phenomenon, most places don't have it anymore; in Ottawa since last year, RO residents will admit patients but then hospitalists take over the care. Confirming Costco fries as country wide though :D

I learned that rad onc residents in Canada: 1. Do 2 med onc & 2 pall care rotations. 2. There's an inpatient rad onc service staffed by rad onc res/attendings - & rad onc res take in house call & carry code pager overnight! #1 sounds great, #2 would prob cause mutiny in US.

@HewittJSB @hyperionrecords @AppleMusic Thank you Ms. Hewitt, and just to be clear that is a @AppleClassical feature. Really enjoyed your concert at the NAC last winter!

I often get comments from my fans about the CD notes I write myself and take such time over. They are important to me, and I hope add to your listening enjoyment. Now every @hyperionrecords booklet is available on @AppleMusic which is great! Just click on the book icon top right.

A vaccine has essentially eliminated a dreadful form of cancer. Extraordinary.

When the #radonc contours only the PTV

@KylePorterCBS Rich beem cool dude too

Phil talking hook winds, slice winds, into and down. I can’t get enough. Also at the end: “I’m not a betting man as you know [pause …] I guess that’s probably not true.”

Je vous recommande cet article de La Presse : Des médecins implorent le ministre Dubé d’agir lp.ca/baQgxY?sharing…

Wonderful results - can't wait to see more details. BUT- when/why do we endorse PFS as the valid primary endpoint in drug trials in the definitive treatment, but insist on OS for some Ph3 RT trials in metastatic cancer? As we often argued to many protocol review committees, RT is a form of local therapy and is meant for improving local control. Therefore PFS should be a valid endpoint in some situations if accompanied by other meaningful patient-centered measures (PRO/QOL etc.). @JYangMDPhD @seanmmcbride @VPrasadMDMPH @PercyLeeMD @DrPOGaudreau @DrewMoghanaki @IyengarPuneeth @Dr_AliHosni @DrLesterColl @DavidSherMD @jamesbyu @QuynhNguyenMD @Josh_Waka @xrtGenomics FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer fda.gov/drugs/resource…

Excellent editorial !! Yes, excluding some therapy whenever it is not needed is necessary.Doesn't matter which modality it is.But the evidence should be strong enough.Not to forget the fact that trial setting is not = real world setting always.

@CTuscanoMD for sequetials phases 2-3 would be very watchful of rectal filling (CBCT), think about replanning for the boosts if rectum was filled on the 1st planning scan and emptier at the end of the first 25 fractions...

@CTuscanoMD Would stick to normofx. 45 to pelvic nodes and mesorectum and 50 Gy to prostatic fossa, sequential boost 64 to prostatic fossa, and 2nd sequential boost 70-74 Gy to macro disease limited by constraints to the the rectum.

A tricky question for #radonc folk expert in #PCa.A 63 y.o. with BR (0.8 ng/mL) underwent a PSMA PET that demonstrated 2 focal uptakes : - Prostate lodge - Perirectal ( no margin with right lateral rectal wall, see the pic). How would you approach this anatomical conondrum?